We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Antisoma | LSE:ASM | London | Ordinary Share | GB0055696032 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.325 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
11/2/2011 09:09 | 'Because companies always trade at multiples of a premium to their cash level' really? even companies with next to nothing?? SAR is priced up because people are excited about their assets. Too excited IMO, but that's the way it goes Cash is king, but when the seller is desperate and has no choice, do you really think people will pay more than cash for it?? seriously? Like I've said, IMO Ora will reverse something into it There's no reason this will be at any premium to the cash level - once you factor in remaining spending requirements Deal at 2.5p/share? Furthermore, if people like you expect a takeover, you may find sellers if the reverse takeover just means being invested in another biotech - with plans to spend through the cash. Many biotechs actually sit at a discount to cash at times for that reason. | the_doctor | |
11/2/2011 09:01 | Because companies always trade at multiples of a premium to their cash level. In the case of ASM they have an amount of cash that others can only dream of. Sareum are capitalised £27 million. They raised £500K on the back of frenetic buying. Its the only cash they have plus an unprovable compound tested on a rat for goodness sake. ASM are capitalised at £15 million and have £23 million in the bank. The directors of SAR would gladly swap places with the directors of ASM any day. Anyway enough said for now and just watch the shareprice take care of itself. Cash is king. | pwhite73 | |
11/2/2011 08:42 | I stand by my 5597 You have no idea what they're might reverse in. I fail to see why it would be on premium terms for ASM holders, although the private co would of course accept some discount as in a traditional placing | the_doctor | |
11/2/2011 07:40 | hope you guys listened to me re sar if not ABH. new rns out, more contracts to come. etc. | dahmmy | |
11/2/2011 07:01 | with £23 million cash feel that could attract another biotech who are in the cancer research area to merge into and its in the mature stage and not listed...well definately looks good as the bod promised to increase value for the share and the stakeholder..... | quraishim | |
10/2/2011 23:43 | 'With its cash balance of £23 million it stands head and shoulders above 98% of other AIM stocks' dont be daft 1. x% of the cash will be spent 2. it has very little else IMO, ORA is looking to reverse a private company in here, giving them a listing and cash They will not IMO be buying ASM for cash. Holders will get a share in a new biotech. Lastly, IMO, the terms of a reverse takeover could be poor for holders here. ORA's main concern would probably be the private company holders and could even push through terms that give shareholders here a negative result. Be warned. There could be upside, but downside scenarios exist too. | the_doctor | |
10/2/2011 21:57 | The company is slowing being taken over. With its cash balance of £23 million it stands head and shoulders above 98% of other AIM stocks. There are many options available to increase shareholder value. ORA are now holding 16%. | pwhite73 | |
10/2/2011 16:56 | 2.8m sell goes through on close mms up the price???? | freddie ferret | |
10/2/2011 15:17 | Someone has just bought around 800,000 in 25,124 size deals. Buys strongly leading sells. | freddie ferret | |
10/2/2011 10:20 | asm sleeping while biotechs are on fire, £20 million cash rich...3 products are on trial........dyor | quraishim | |
09/2/2011 14:21 | Lots of medium sized trades today good volume buys lead sells. | freddie ferret | |
09/2/2011 14:08 | As I said mentally defective. Clubman - 8 Feb'11 - 17:01 - 5573 of 5589 Clubby was a thick CEO until retirement selling his private leisure Company of nightclubs, pubs, and bars built up over 30 years, and guess what Doc this thicko sold out to Luminar Leisure PLC for £26m Remind me what it is you do. See you Thursday I am off to the beach Wednesday Clubman - 8 Feb'11 - 17:06 - 5574 of 5589 Oh doc I forgot to mention Clubby won £20,000 cash last year in the ETX Capital Beat the Broker competition. Not bad for a boy who left school at 15 with no qualifications. | freddie ferret | |
09/2/2011 11:18 | Oh well, I guess the Pharma herd may come over here next if someone posts a ramp or two. They've been everywhere else today. | loverat | |
09/2/2011 10:50 | GL to all Sareum holders and hope they make pots of money. But with mrkt cap of 50+ml and pre-clinical data there is some way to go. I reckon at 14ml mrkt cap (discounting costs to be incurred), income on out-licnsed products, ip and it's present stable (which are worth something-anyone's guess) asm are worth a punt. And of course the value of a listing. In at 2.3 approx. gla imo | cumnor | |
09/2/2011 06:42 | PWhite73, sure, cash is useful, but I dont see why many would pay a premium for it. ASM isnt in a position to demand It also means that you'll get paper shares not cash | the_doctor | |
09/2/2011 01:34 | Sareum Holdings, the cancer drug specialist, soared 240 per cent to 1.65p after very positive results from its leukaemia study. Antisoma eased 5.6 per cent to 2.28p. However, after the market closed Richard Griffiths' Ora Capital declared a raised holding of almost 16 per cent in the struggling cancer drug company | pwhite73 | |
08/2/2011 22:56 | The fact is the company at 31 December 2010 had £23.4 million in cash. Even if they settle all liabilities and make staff redundant leaving cash at £14 million it is still worth investing a company three times that value into ASM. Cash is everything in these tight capital markets. Look at all the other drug, oil or mineral resource companies in your portfolio. How far are they from commercialisation, look at their market cap and look at how much cash they have. Kefi are valued at £22 million and raised £1.8 million in cash recently for working capital. Gold production on the 1.1 million oz is years away if they ever get there. Ora have forked out £2,250,000 for 15% of the company. Ora are not the only outfit that would be attracted to ASM's cash. As the CEO said:- 'Once the drug failed, the phone started to ring,' explains Edwards. 'As a much smaller company, we shall be interested in evaluating what may come along.' Cash is equivalent to a stock market value of multiples. Sit tight. | pwhite73 | |
08/2/2011 18:06 | 'Yes' comedy | the_doctor | |
08/2/2011 18:03 | the_doctor - 8 Feb'11 - 17:57 - 5580 of 5581 Do people go to a football match in the hope of determining the score? Does anyone know what the fu*k he's on about,lol,I'm off. | duncandisorderly | |
08/2/2011 18:00 | Yes, the players and the management. | gazmat | |
08/2/2011 17:57 | Do people go to a football match in the hope of determining the score? | the_doctor | |
08/2/2011 17:41 | "duncandisorderly - 8 Feb'11 - 17:29 - 5576 of 5578 For the life of me I can't understand why all you,"non holding idiots"spend hour upon hour clogging up these sites with your pointless arguments.P*ss off the lot of you and leave these sites to genuine holders." I really don't believe anybody posts here unless there is an ulterior motive - PIs tilting at windmills in the hope of moving the share price to their advantage or paid posters doing their masters bidding in an effort to shift sentiment. | gazmat |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions